近日，Julie A. E. Irving团队于 Leukemia 发表题为 Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia ...

More than 140,000 articles have been published on molecules that mediate the intrinsic and extrinsic apoptotic cascades, such as BCL-2, TNF, NF-κB and p53. This interest in part stems from the ...

p53 is a common denominator among human cancers. How was it discovered? What are the persistent questions about its function? Aa Aa Aa It seems nearly impossible for a normal cell to become a ...

Under normal, unstressed conditions, a key negative regulator of p53 is MDM2, which binds to the ... SOCS2 = suppressor of cytokine signalling 2; SOD2 = superoxide dismutase; [Mn] = mitochondrial ...

Alrizomadlin is under clinical development by Ascentage Pharma Group International and currently in Phase II for Non-Hodgkin Lymphoma.

INR:5899. left arm chinaman The president of a top three hospital surrendered, the distributor was interviewed... The whole country cracked down on kickbacks fo ...

Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Myelodysplastic Syndrome.